

January 29, 2024

### Transfer of Three Marketed Products in Japan

Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group, concluded an agreement with Fuji Pharma Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President & CEO: Takayuki Iwai; hereinafter, "Fuji Pharma") as of January 29 to transfer the domestic manufacturing and marketing authorization, manufacturing and marketing rights, etc. to Fuji Pharma for three products: Azanin, Cholebine and Surfacten.

The three products to be transferred this time are as follows.

	Brand name	Therapeutic category
1	Azanin Tablets 50 mg	Immunosuppressants
2	Cholebine Tablets 500 mg, Cholebine Mini 83%	Therapeutic agent for hypercholesterolemia
3	Surfacten 120 mg for Intratracheal Injection	Therapeutic agent for neonatal respiratory distress syndrome

MTPC's MISSION is "Creating hope for all facing illness." To achieve this, we continuously consider the optimal allocation of management resources to build a stable management base. Under the circumstances, we have decided to transfer these three products to Fuji Pharma. Sales will be transferred to Fuji Pharma in the second quarter of fiscal 2024 and thereafter. Until the transfer of sales of these products is completed, MTPC will collaborate with Fuji Pharma to provide information on these products, promote their proper use, and ensure their stable supplies.

*Contact:*  
Mitsubishi Chemical Group Corporation  
Corporate Communications Division  
Osaka Corporate Communications Department  
+81-6-6205-5119

■ About Fuji Pharma Co., Ltd.

Fuji is a Tokyo Stock Exchange (TSE) listed, Japan - based pharmaceutical company mainly engaged in the manufacture and sale of prescription based pharmaceutical products. Since our establishment in 1965, Fuji has promoted corporate philosophy that "We help people lead healthy lives by offering excellent pharmaceuticals." and "Our corporate growth is proportional to our personal growth." Fuji focuses on the field of women's healthcare with a wide variety of new and generic drugs for women's specific diseases, from infertility perinatal period, dysmenorrhea, to menopausal disorders. Fuji also provide various product lineup in acute medical to provide new treatment options to patients and medical professionals. Fuji will continue our efforts to help people lead healthy lives. For further information, please visit our website <https://www.fujipharma.jp/english/ir/>